Abstract
Introduction: The phase III TITAN trial evaluated the use of darunavir with low-dose ritonavir (DRV/r) 600/100mg twice daily (bid) compared with lopinavir with low-dose ritonavir (LPV/r) in treatment-experienced, lopinavirnaive patients. This study estimates the cost effectiveness of DRV/r from a US societal perspective when compared with LPV/r in treatment-experienced patients with a profile similar to those TITAN patients who had one or more International AIDS Society — USA (IASUSA) primary protease inhibitor (PI) resistance-associated mutations (RAMs) at baseline. This population had less advanced HIV disease and a broader range of previous PI exposure/failure (0–≥2 PIs) at enrolment than those in the darunavir phase IIb POWER trials.
Methods: An existing Markov model containing six health states defined by CD4 cell count range (>500, 351–500, 201–350, 101–200, 51–100 and 0–50 cells/mm3) and an absorbing state of death was adapted. Baseline demographics, CD4 cell count distribution and antiretroviral drug usage, virological response (at week 24), and immunological response estimates and matching transition probabilities were based on data collected directly from the one or more IASUSA PI mutation subpopulation during the first 48 weeks of the TITAN trial, as well as from published literature. Patients were assumed to switch to a regimen containing tipranavir plus an optimized background regimen after treatment failure. For each CD4 cell count range or health state, the utility values, HIV and non-HIV-related mortality rates, and non-antiretroviral-related cost of HIV care estimates were derived from published literature. Unit costs were derived from official local sources. A lifetime horizon was taken in the base-case analysis.
Results: The base-case analysis predicted discounted quality-adjusted survival gains of 0.493 quality-adjusted life-years (QALYs) for DRV/r compared with LPV/r, resulting in an incremental cost-effectiveness ratio (ICER) of US$23 057 per QALY gained over a lifetime horizon. Probabilistic sensitivity analysis indicated a 0.754 probability of an ICER below the threshold of US$50 000 per QALY gained. DRV/r remained cost effective over all parameter ranges tested in extensive one-way sensitivity analyses and variability analyses, which examined the impact of input parameter uncertainty and changes in model assumptions and treatment patterns, respectively. Shortening the model time horizon had the largest impact on the ICER, reducing it most notably to US$4919 with a 10-year time horizon.
Conclusion: From a US societal perspective and based on an analysis of the patients with primary IASUSA PI RAMs enrolled in the darunavir phase III TITAN trial, a highly active antiretroviral therapy (HAART) regimen containingDRV/r 600/100mg bid is estimated to be a cost-effective therapy when compared with a HAART regimen containing LPV/r, for the management of treatment-experienced, PI-resistant, HIV-infected adults with a broad range of previous PI use/failure.
Similar content being viewed by others
References
Braithwaite RS, Justice AC, Chang CC, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med 2005; 118: 890–8
Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr 2006; 43: 451–7
Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44: 990–7
Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11–19
Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 1023–35
Mocroft A, Ledergerber B, Viard JP, et al. Time to virological failure of 3 classes of anti-retrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis 2004; 190: 1947–56
Sabin CA, Scullard G, Easterbrook P, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005; 330: 695–9
European AIDS Clinical Society (EACS). 2009 guidelines for the clinical management and treatment of HIV infected adults in Europe; 2009 [online]. Available from URL: http://www.europeanaidsclinicalsociety.org/guidelinespdf/EACS-EuroGuidelines2009FullVersion.pdf [Accessed 2009 Dec 10]
Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association guidelines for treatment of HIV-infected adults with antiretroviral therapy, 2006. HIV Med 2006; 7: 487–503
US Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents (USDHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2008 Jan 29 [online]. Available from URL: http://AIDSinfo.nih.gov [Accessed 2009 Dec 10]
DeJesus E, LaMarca A, Sension M, et al. The CONTEXT study: efficacy and safety of GW433908/r in PI-experienced subjects with virological failure (24 week results) [abstract 178]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 1013; Boston, MA, USA
Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther 2005; 10: 735–43
Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavirritonavir versus lopinavirritonavir, each in combination with abacavirlamivudine, for initial treatment of HIV infection over 48 weeks: a randomised noninferiority trial. Lancet 2006; 368: 476–82
Johnson MA, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19: 685–94
Walmsley S, Bernstein B, King M, et al. Lopinavirritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039–46
Madruga JV, Berger D, McMurchi M, et al. Efficacy and safety of darunavir/ritonavir compared with that of lopinavir/ritonavir at 48 weeks in treatment-experienced, HIV infected patients in TITAN: a randomized controlled phase III trial. Lancet 2007; 370: 49–58
International AIDS Society USA (IASUSA). Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society — USA panel. JAMA 2006; 296: 827–43
Berger DS, Northland R, Scribner A, et al. Effect of baseline factors on virological response to darunavir/r and lopinavir/r at week 48 in TITAN [abstract P7.3/27]. 11th European AIDS Conference; 2007 Oct 2427; Madrid, Spain
Tibotec Pharmaceuticals. Results of TITAN Phase III clinical trial for darunavir/r. City: Mechelen, Belgium. Tibotec Pharmaceuticals. Data on file, 2007
Gallant JE. Approach to the treatment-experienced patient. Infect Dis Clin North Am 2007; 21: 85–102
Mauskopf J, Brogan A, Martin S, et al. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. PharmacoEconomics 2010; 28 Suppl. 1: 83–105
Phillips AN, Lundgren JD. The CD4 lymphocyte count and risk of clinical progression: the T cell in HIV infection and disease. Curr Opin HIV AIDS 2006; 1: 43–9
Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV health care in the HAART era [abstract 537]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 59; Denver, Colorado, USA
Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004; 5: 294–304
Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA Study: an observational study. Lancet 2003; 362: 22–9
Jensen-Fangel S, Pedersen L, Pedersen C, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 2004; 18: 89–97
Deeks SG, Barbour JD, Grant RM, et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16: 201–7
Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microl in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41: 361–72
Benzie AA, Bansi LK, Sabin C, et al. Viral rebound in patients on antiretroviral therapy with viral suppression: association with extent of previous virological failure and time with viral suppression [abstract O9]. 12th Annual Conference of the British HIV Association; 2006 29 Mar1 Apr; Brighton, UK
Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51–62
Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavirritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised openlabel trials. Lancet 2006; 368: 466–75
Cahn P, and the RESIST 2 Study Team. 24-Week data from RESIST 2: Phase 3 study of the efficacy and safety of background therapy plus tipranavir/ritonavir (/r) or optimized ritonavir-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV+ patients [abstract PL14.3]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 1418; Glasgow, UK
Cooper D, Hicks C, Cahn P, et al. 24-Week study analyses: the efficacy of tipranavir/ritonavir (TPV/r) is superior to lopinavir/ritonavir (LPV/r), and the TPV/r treatment is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR) [abstract 561]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 2225; Boston, Massachusetts, USA
Hicks CB and the RESIST-1 study team. A phase 3 randomized, controlled, open-label multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data [abstract 3726]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 31Nov 2; Washington DC, USA
Garcia F, de Lazzari E, Plana M, et al. Long-term CD4 T-cell response to highly active antiretroviral therapy according to baseline CD4 T-cell count. J Acquir Immune Defic Syndr 2004; 36: 702–13
Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increased in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 1907–15
Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163: 2187–95
Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003; 17: 963–9
Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 168–75
US Department of Labor, Bureau of Labor Statistics. US Medical Care Consumer Price Index; 2008 [online]. Available from URL: http://data.bls.gov/cgi-bin/surveymost?cu [Accessed 2009 Dec 10]
Tibotec Pharmaceuticals. Results of POWER 1 and 2 Phase II clinical trials for darunavir/r. City: Mechelen, Belgium. Tibotec Pharmaceuticals. Data on file, 2005
Maggiolo F, Migliorino M, Pirali A, et al. Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment. J Acquir Immune Defic Syndr 2000; 25: 36–43
Yamashita TE, Phair JP, Muåoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15: 735–46
Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavirritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169–78
De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009; 23: 1829–40
Cook J, Dasbach E, Coplan P, et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retroviruses 1999; 15: 499–508
Medispan. Price-check PC; [online]. Available from URL: http://www.medispan.com/index.aspx [Accessed 2009Dec 10]
Analy$ource® Online; [online]. Available from URL: http://www.analysource.com [Accessed 2009 Dec 10]
Yang Z, Norton EC, Stearns SC. Longevity and health care expenditures: the real reasons older people spend more. J Gerontol 2003; 58: S2–10
Moeremans K, Annemans L, Löthgren M, et al. Cost effectiveness of darunavir/ritonavir 600/100mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. PharmacoEconomics 2010; 28 Suppl. 1: 107–28
Food and Drug Administration (FDA): Press Release: FDA approves darunavir; 2006 Jun 23 [online]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108676.htm [Accessed 2009 Dec 10]
European Commission Community register of medicinal products for human use. PREZISTA; [online]. Available from URL: http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents/community-register/html/h380.htm [Accessed 2009 Dec 10]
Liu GG, Yin DD, Lyu R, et al. Economic costs of HIV infection: an employers perspective. Eur J Health Econ 2002; 3: 226–34
Sendi P, Schellenberg F, Ungsedhapand C, et al. Productivity costs and determinants of productivity in HIV infected patients. Clin Ther 2004; 26: 791–800
Ahsan N, Langhoff E. Immunopathogenesis of human immunodeficiency virus. Semin Nephrol 1998; 18: 422–35
Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med 2007; 8: 96–104
Simpson KN, Chumney ECG, Hicks CB, et al. Cost effectiveness of tipranavir in treatment-experienced HIV patients in the USA [abstract PIN10]. 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2006 May 2024; Philadelphia, Pennsylvania, USA
Hill A, Moyle G. Relative antiviral efficacy of ritonavirboosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259–64
Simpson KN, Jones WJ, Rajagopalan R, et al. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Clin Drug Invest 2007; 27: 443–52
Rockstroh J, Clumeck N, Spinosa-Guzman S, et al. Darunavir (TMC114)/r has tolerability and efficacy benefits for treatment-experienced patients compared with control PIs; overview of the POWER trials [abstract P28]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 1216; Glasgow, UK
Sherman DS, Fish DN. Management of protease inhibitorassociated diarrhea. Clin Infect Dis 2000; 30: 908–14
Committee forMedicinal Products for HumanUse (CHMP) of the European Medicines Evaluation Agency (EMEA). Summary of positive opinion for raltegravir; 2007 Nov 27 [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/press/pr/52210907en.pdf[Accessed 2009 Dec 10]
Committee forMedicinal Products for HumanUse (CHMP) of the European Medicines Evaluation Agency (EMEA). Summary of positive opinion for maraviroc; 2007 [online]. Available from URL: http://www.ema.europa.eu/humandocs/Humans/EPAR/celsentri/celsentri.htm [Accessed 2009 Dec 10]
Food and Drug Administration (FDA) Press Release. FDA approves new antiretroviral drug; 2007 Oct 16 [online]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109008.htm [Accessed 2009 Dec 10]
Food and Drug Administration (FDA) Press Release. FDA approves novel antiretroviral drug; 2007 Aug 6 [online]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108960.htm [Accessed 2009 Dec 10]
Horne R, Clotet B, Cohen C, et al. Treatment-experienced patient perceptions of self-injectable therapy [abstract PE7.3/25]. 10th European AIDS Clinical Society Conference; 2005 Nov 1114; Dublin, Ireland
Loveday C, MacRae E. Susceptibility of a protease inhibitor (PI) treatment-experienced UK clinical cohort to TMC-114 [abstract PL2.2]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 1216; Glasgow, UK. 2006
Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 2007; 60: 885–8
Mitsuya Y, Liu TF, Rhee SY, et al. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis 2007; 196: 1177–9
Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389–97
Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002; 31 (Suppl.): S123–7
Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive, HIV-1-infected patients. Antiviral Ther 2003; 8: 339–46
Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrob Chemother 2006; 58: 235–42
Acknowledgements
The authors are grateful to Tony Vangeneugden, Ben Van Baelen, Els De Paepe, Eric Lefebvre, Sabrina Spinosa-Guzman, Frank Tomaka, Piet De Doncker and the rest of the darunavir study team at Tibotec Pharmaceuticals, Mechelen, Belgium, for their contributions in analysing and generating the TITAN-specific efficacy data included in this analysis. The authors also acknowledge Catherine Elliott (medical writer, Gardiner-Caldwell Communications, Macclesfield, UK) for her editorial support. Finally, they thank the study investigators, the patients and their families for their participation and support during the TITAN trial. This project was supported financially by Johnson & Johnson Pharmaceutical Services.
AB, JM and SET, employees of RTI Health Solutions, have received grant support from Janssen-Cilag, the manufacturer of darunavir, to assist with the preparation of the manuscript. They were not restricted by Janssen-Cilag in their analysis or in their interpretation of the final results. ES is an employee of Johnson & Johnson Pharmaceutical Services, Beerse, Belgium, and owns stock options and shares in this company.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brogan, A., Mauskopf, J., Talbird, S.E. et al. US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial. Pharmacoeconomics 28 (Suppl 1), 129–146 (2010). https://doi.org/10.2165/11587490-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11587490-000000000-00000